#10x chromium connect update#
#10x chromium connect skin#

New popup alert when selecting “Expert” instruction level.

New assay setup loading from previously canceled run during loading phase-allows users to selectively decrease the number of samples in a Chromium Connect run.

#10x chromium connect update#

“But there’s a certain fraction of childhood diseases that could be eradicated by in utero delivery.New Software Update: We have improved the Chromium Connect system and encourage you to update today! To access the latest quarterly update and support improvements on Chromium Connect, we are asking that all users update their Chromium Connect instrument to the latest software version (v2022.12.30). However, a big challenge that remains for these types of approaches is that people are hesitant to experiment on unborn children, said Murthy.

“It’s much, much easier to transfer to 10 cells than it is 10 million cells,” he said.

Murthy explained that by targeting progenitors, the technique could potentially target cells throughout the body more easily than conventional gene therapy delivery techniques used in adults. Niren Murthy, a bioengineer at the University of California, Berkeley who was not involved in the study, said that this technology has a lot of potential. “The change we made could last throughout the mouse’s entire life.” This indicated to the researchers that they had successfully targeted progenitor cells within the skin.

#10x chromium connect skin#

“We could see the persistence of the effect on the skin as the mouse got older,” Peranteau said. “The earlier we delivered the lipid nanoparticles, the more robust expression we could achieve in the skin,” Peranteau said. When the mice were born, the researchers used fluorescence microscopy to confirm that skin cells throughout the body brought in the nano particles’ mRNA cargo. “We did this at different gestational ages with the hypothesis that the earlier you’re able to do it, the more accessible the skin progenitor cells are and the easier they are to target,” Peranteau said. (The mouse gestational period lasts a total of 20 days.) They used fluorescent Cre-reporter mice for their experiment, meaning that any cells that took up the mRNA packaged in the lipid nanoparticles would fluoresce. The team tackled this challenge by injecting lipid nanoparticles containing mRNA for Cre recombinase into the amniotic fluid of pregnant mice on the ninth, 12th, and 16th day of the gestational period. He said that skin diseases are particularly tricky to treat because health professionals may be limited to targeting a specific area, either by using a topical treatment, like a lotion or cream, or by injecting a drug. William Peranteau, a pediatric surgeon at the Children’s Hospital of Pennsylvania (CHOP) and coauthor of the work, and his team are interested in studying novel therapies for genetic diseases that affect patients shortly after birth. 3 Previous studies have used lipid nanoparticles to shuttle genetic material to organs like the lungs, liver, and heart in utero. Pegylated lipids, phospholipids, and cholesterol all help stabilize the particle, contribute to its structure, and fuse to cells in the body, allowing the particles to dump their contents inside. Lipid nanoparticles are tiny shells made of positively charged lipids, which bind to the negatively charged backbone of their mRNA cargo. Combined with gene editing machinery like CRISPR, the technology may one day lead to treatments for genetic skin diseases before babies are born. 2 At this year’s American Society of Gene and Cell Therapy conference, researchers presented preliminary work suggesting that lipid nanoparticles could one day deliver mRNA-based gene therapies to treat skin diseases in utero.īy injecting lipid nanoparticles directly into the amniotic fluid of pregnant mice, the researchers successfully delivered mRNA molecules to fetal skin. 1 One example is epidermolysis bullosa, which causes the skin to blister and break, leaving gaping, slow-healing wounds. People with genetic skin diseases are frequently symptomatic since birth, and such diseases can be severe, chronic, and hard to treat.